文献速递糖尿病

利用人工智能在公开数据上辅助实施1型糖尿病筛查

Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available data.
PubMed 文献 · Diabetologia · 2024-02-14

本文讨论人工智能(AI)在1型糖尿病筛查实施中的潜在作用,介绍ASSET公私联合体围绕筛查与精准医学预防的研究方向。作者通过开放论坛独立讨论筛查关键问题,认为AI有潜力变革1型糖尿病筛查,帮助识别高风险个体并设计随访计划,希望该倡议促进进一步研究。

要点

  • AI有潜力帮助识别1型糖尿病高风险个体并辅助设计个体化随访计划。
  • ASSET联合体旨在研究AI如何推动精准医学方法用于1型糖尿病预防。
  • 作者希望该倡议能促进这一及时课题的进一步研究。

核心结论

  • 总体而言,AI有潜力变革1型糖尿病筛查,尤其有助于识别疾病风险增加的个体并辅助设计适当的随访计划。
  • 作者希望该倡议能促进这一非常及时课题的进一步研究。

研究设计与样本

  • 本文为来自1型糖尿病领域的研究者和临床医生在开放论坛上独立讨论筛查关键问题并为ASSET提供建议的总结。
  • ASSET(AI for Sustainable Prevention of Autoimmunity in the Society)是一个公私联合体,旨在推动1型糖尿病筛查相关研究及AI驱动精准医学预防方法的实施。

主要发现

  • 筛查项目需证明检测变量可实现准确风险预测、建立个体化风险知情监测计划,并具备操作可行性、成本效益和人群层面接受度。
  • 会议讨论了AI在分析观察性队列研究纵向数据以改进和个体化筛查设计方面的潜在用途。
  • 关键议题包括AI能否让研究界和产业界利用大型公开数据存储库设计筛查项目,以早期发现高风险个体并开展预防疗法的临床评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The type 1 diabetes community is coalescing around the benefits and advantages of early screening for disease risk. To be accepted by healthcare providers, regulatory authorities and payers, screening programmes need to show that the testing variables allow accurate risk prediction and that individualised risk-informed monitoring plans are established, as well as operational feasibility, cost-effectiveness and acceptance at population level. Artificial intelligence (AI) has the potential to contribute to solving these issues, starting with the identification and stratification of at-risk individuals. ASSET (AI for Sustainable Prevention of Autoimmunity in the Society; www.asset.healthcare ) is a public/private consortium that was established to contribute to research around screening for type 1 diabetes and particularly to how AI can drive the implementation of a precision medicine approach to disease prevention. ASSET will additionally focus on issues pertaining to operational implementation of screening. The authors of this article, researchers and clinicians active in the field of type 1 diabetes, met in an open forum to independently debate key issues around screening for type 1 diabetes and to advise ASSET. The potential use of AI in the analysis of longitudinal data from observational cohort studies to inform the design of improved, more individualised screening programmes was also discussed. A key issue was whether AI would allow the research community and industry to capitalise on large publicly available data repositories to design screening programmes that allow the early detection of individuals at high risk and enable clinical evaluation of preventive therapies. Overall, AI has the potential to revolutionise type 1 diabetes screening, in particular to help identify individuals who are at increased risk of disease and aid in the design of appropriate follow-up plans. We hope that this initiative will stimulate further research on this very timely topic.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Teixeira PF, Battelino T, Carlsson A, et al. Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available data. Diabetologia. 2024. PMID: 38353727. doi:10.1007/s00125-024-06089-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。